Rory Shallis, MD

2026

• Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

  Shallis R. Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant. Haematologica 2026 PMID: 42687836, DOI: 10.3324/haematol.2026.301785.

  Peer-Reviewed Original Research

• Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study

  Badar T, Foran J, Jamy O, Lin C, Patel A, Wang Y, Kumar M, Shallis R, Diebold K, Coltoff A, Goldberg A, Bewersdorf J, Zabel K, Foucar C, Abaza Y, Murthy G, Palmisiano N, DuVall A, Kota V, Patel S, Zeidan A, Murthy H, Kharfan-Dabaja M, Atallah E, Litzow M. Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study. Leukemia 2026, 1-9. PMID: 42675141, DOI: 10.1038/s41375-026-03119-6.

  Peer-Reviewed Original Research

  Altmetric

• Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

  Rolles B, Bewersdorf J, Kewan T, Blaha O, Stempel J, Al Ali N, DeZern A, Sekeres M, Uy G, Urrutia S, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Barua S, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Wang E, Harris A, Amaya M, Hawkins H, Ball S, Grenet J, Abedi P, Shimony S, Lindsley R, Xie Z, Madanat Y, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al‐Rabi K, Halahleh K, Hiwase D, Diez‐Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al‐Kali A, Ogawa S, Nannya Y, Della Porta M, Komrokji R, Zeidan A, Stahl M. Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS). American Journal Of Hematology 2026 PMID: 42657925, DOI: 10.1002/ajh.70474.

  Peer-Reviewed Original Research

  Altmetric

• The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

  Shallis R, VanOudenhove J, Chandhok N, Watts J, Jeyakumar D, Reed D, Bewersdorf J, Durecki D, Boerner S, Little R, Gore S, Li J, Bao X, Chen L, Ghatak S, Prebet T, Bindra R, Zeidan A, Halene S. The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes. British Journal Of Haematology 2026 PMID: 42644317, DOI: 10.1111/bjh.70756.

  Peer-Reviewed Original Research

• Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms

  Katamesh B, Shallis R. Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms. Current Oncology 2026, 33: 506. DOI: 10.3390/curroncol33090506.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

• Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014–2024)

  Joshi U, Zahra F, Patel P, Al Ali N, Thompson Z, Pakasticali N, Song J, Agrawal V, Shallis R, Xie Z, Yun S, Kuykendall A, Padron E, Walker A, Sallman D, Komrokji R, Lancet J, Hussaini M, Chan O. Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014–2024). Annals Of Hematology 2026 PMID: 42393270, DOI: 10.1007/s00277-026-07145-3.

  Peer-Reviewed Original Research

• Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

  Bewersdorf J, Kewan T, Wei W, Rudra Gupta T, Stempel J, Al Ali N, DeZern A, Sekeres M, Uy G, Urrutia S, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Hawkins H, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Ball S, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta M, Komrokji R, Zeidan A. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database. Blood Cancer Journal 2026, 16: 155. PMID: 42373605, PMCID: PMC13575243, DOI: 10.1038/s41408-026-01543-6.

  Peer-Reviewed Original Research

  This study investigates the impact of combining hypomethylating agents with venetoclax for high-risk myelodysplastic syndromes, finding increased remission rates but no significant overall survival benefit.

  Full Summary

• Limited Survival Benefit and High Healthcare Utilization With AML‐Directed Therapy in Older Patients With TP53 ‐Mutated Acute Myeloid Leukemia

  Zhang T, Ge A, Hutchinson L, Higgins A, Miron P, Shallis R, Patel S. Limited Survival Benefit and High Healthcare Utilization With AML‐Directed Therapy in Older Patients With TP53 ‐Mutated Acute Myeloid Leukemia. American Journal Of Hematology 2026, 101: 2475-2480. PMID: 42332361, PMCID: PMC13428370, DOI: 10.1002/ajh.70422.

  Commentaries, Editorials and Letters

  Altmetric

• Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study

  Filimon S, Ghamari A, Vakilpour A, Patel R, Achar R, Akhter N, Shallis R, DeCara J, Altman J, Smith A, Matthews A, Lai C, Brunner A, Farina K, Gilman H, Neilan T, Upadhyay D, Chittams J, Anazco F, Patel A, Tremblay D, Scherrer-Crosbie M. Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study. JACC Advances 2026, 5: 102821. PMID: 42312783, PMCID: PMC13308248, DOI: 10.1016/j.jacadv.2026.102821.

  Peer-Reviewed Original Research

  Altmetric

• NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

  Pollyea D, Altman J, Assi R, Bachiashvili K, Bhatt V, Fathi A, Fedorov K, Foran J, Gojo I, Goldberg A, Hall A, Jonas B, Levine M, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival M, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone R, Thota S, Uy G, Walker A, Wang E, Awotiwon A, Roth S, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. Journal Of The National Comprehensive Cancer Network 2026, 24: 222-229. PMID: 42297017, DOI: 10.6004/jnccn.2026.0028.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Altmetric

  MeSH Keywords